stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) EV/Sales
As of 5 November 2026, Tango Therapeutics, Inc. (TNGX) trades at a EV/Sales of 34.7×. Over the past ten years it has ranged from −5.5× (September 2022) to 69.6× (June 2026); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.0× | 480.76% |
| FY2024 | 1.9× | (88.59%) |
| FY2023 | 16.6× | 49.85% |
| FY2022 | 11.1× | 111.81% |
| FY2021 | 5.2× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 11.0× | (6.16%) |
| Sep 2025 | 11.7× | (26.04%) |
| Jun 2025 | 15.8× | — |
| Mar 2025 | −1.6× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PBLS Parabilis Medicines, Inc. compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 2.2× |
| IOVA Iovance Biotherapeutics, Inc. compare | 8.5× |
| TNGX Tango Therapeutics, Inc. | 34.7× |
| ABCL AbCellera Biologics Inc. compare | 43.5× |
| XENE Xenon Pharmaceuticals Inc. compare | 169× |
| RLAY Relay Therapeutics, Inc. compare | 231× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement